Redigerer Galcanezumab (avsnitt)

== Referanser ==
<references>
<ref name="CNBC">{{Kilde avis|url=https://www.cnbc.com/2018/09/28/us-fda-approves-lilly-migraine-drug-at-a-price-that-is-the-same-as-its-rivals.html|tittel=US FDA approves Lilly migraine drug at a price that is the same as its rivals|dato=28. september 2018|utgiver=CNBC|besøksdato=29. september 2018|byrå=Reuters|avis=CNBC|etternavn=|fornavn=|side=|sitat=}}</ref>

<ref name="Emgality EPAR">{{Kilde www|url=https://www.ema.europa.eu/en/medicines/human/EPAR/emgality|tittel=Emgality EPAR|besøksdato=28.04.2020}}</ref>

<ref name="Erman">{{Kilde www|url=https://www.reuters.com/article/us-lilly-emgality-approval-idUSKCN1T52VP|tittel=FDA approves Lilly's migraine drug as first ever cluster headache treatment|besøksdato=28. april 2020|forfattere=|dato=|fornavn=Michael|etternavn=Erman|forlag=Reuters|sitat=}}</ref>

<ref name="FDA">{{Kilde www|url=https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/761063Orig1s000TOC.cfm|tittel=Drug Approval Package: Emgality (galcanezumab-gnlm)|besøksdato=7. desember 2019|arkiv-url=https://web.archive.org/web/20191207202844/https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/761063Orig1s000TOC.cfm|arkivdato=7. desember 2019|forfattere=|dato=|forlag=U.S. [[Food and Drug Administration]] (FDA)|sitat=}}</ref>

<ref name="FDA2019">{{Kilde pressemelding|url=https://www.fda.gov/news-events/press-announcements/fda-approves-first-treatment-episodic-cluster-headache-reduces-frequency-attacks}}</ref>

<ref name="FDA Snapshot">{{Kilde www|url=https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-emgality|tittel=Drug Trials Snapshots: Emgality|besøksdato=7. desember 2019|arkiv-url=https://web.archive.org/web/20191207205725/https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-emgality|arkivdato=7. desember 2019|forfattere=|dato=|forlag=U.S. [[Food and Drug Administration]] (FDA)|sitat=}} </ref>

<ref name="Spreitzer (2017)">{{Kilde artikkel|tittel=Neue Wirkstoffe: Galcanezumab, Fremanezumab und Eptinezumab|publikasjon=Österreichische Apothekerzeitung|dato=3. juli 2017|forfattere=H. Spreitzer|språk=Tysk|hefte=14/2017}}</ref>
</references>